Vaginal chlorhexidine gluconate versus fluconazole for recurrent vulvovaginal candidiasis: A randomized noninferiority trial
PLOS One · 2026
DOI: 10.1371/journal.pone.0340862 ↗Kurz gefasst
Äquivalenzstudie in der Zeitschrift PLOS One, 2026. Verfasst von Cathrin Alvendal und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Sciences, Division of Obstetrics and Gynecology, Karolinska Institutet, Danderyd Hospital, Stockholm, Sweden. Hauptthemen laut MEDLINE: Antifungal Agents, Candidiasis, Vulvovaginal, Chlorhexidine, Fluconazole. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement, Medicinska Forskningsrådet.
Abstract (Originalsprache)
Background
Recurrent vulvovaginal candidiasis (RVVC) is a common condition characterized by frequent relapses, often without a clearly identifiable cause. Fluconazole (FLZ) is the standard treatment but concerns about emerging resistance and drug interaction highlight the need for alternative therapies. Chlorhexidine gluconate (CHG), known for its antifungal and biofilm-disrupting properties, has been proposed as a potential alternative.
Objective
To evaluate the efficacy, tolerability, and microbiome impact of a vaginal CHG formulation compared to oral FLZ in the treatment of RVVC caused by Candida albicans .
Methods
An open label randomized non-inferiority trial was conducted to compare vaginal CHG and FLZ treatments. Primary outcome was negative cultures for C. albicans . Resistance profiles and changes in the vaginal microbiome composition were also assessed.
Results
The study was terminated early due to local irritation associated with CHG and the study design was transitioned into a pilot study. CHG treatment showed comparable efficacy to FLZ in clearing C. albicans infections and preventing recurrences, although the sample size was limited. All 11 participants in the FLZ group cleared the infection after one week treatment, compared to 9 out 11 in the CHG group. No harmful changes to the vaginal microbiome were observed in the CGH or FLZ group. FLZ promoted a shift toward Lactobacillus crispatus dominance, unlike CHG. Notably, 16% of C. albicans isolates exhibited reduced susceptibility or resistance to FLZ.
Conclusion
Due to the limited number of participants, we cannot conclusively determine whether CHG is non-inferior to FLZ in terms of efficacy for clearing acute C. albicans infections or preventing recurrences. While the current CHG formulation caused local irritation and is not suitable for clinical use, its antifungal and biofilm-inhibiting properties remain promising. Further development of less irritative CHG formulations may offer a valuable alternative for RVVC treatment, particularly in the context of rising FLZ resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Clinical Sciences, Division of Obstetrics and Gynecology, Karolinska Institutet, Danderyd Hospital, Stockholm, Sweden.
- Department of Medicine Solna, Division of Infectious Diseases, Karolinska Institutet, Department of Infectious Diseases, Karolinska University Hospital, Center for Molecular Medicine, Stockholm, Sweden.
- Centre for Translational Microbiome Research, Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
- Department of Microbiology, Tumor and Cell Biology, Division of Clinical Microbiology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.
- Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden.
ORCID-Profile: Tyra Hasselrot, Gabriella Edfeldt, Nina Bohm-Starke
Förderung
- Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement
- Medicinska Forskningsrådet
Zitieren
APA
Alvendal, C., Hasselrot, T., Balduck, M., Edfeldt, G., Schuppe-Koistinen, I., Brauner, A., Altman, D., Broliden, K., & Bohm-Starke, N. (2026). Vaginal chlorhexidine gluconate versus fluconazole for recurrent vulvovaginal candidiasis: A randomized noninferiority trial. PLOS One. https://doi.org/10.1371/journal.pone.0340862
Vancouver
Alvendal C, Hasselrot T, Balduck M, Edfeldt G, Schuppe-Koistinen I, Brauner A, et al. Vaginal chlorhexidine gluconate versus fluconazole for recurrent vulvovaginal candidiasis: A randomized noninferiority trial. PLOS One. 2026. doi:10.1371/journal.pone.0340862
BibTeX
@article{Alvendal2026,
author = {Alvendal, Cathrin and Hasselrot, Tyra and Balduck, Margaux and Edfeldt, Gabriella and Schuppe-Koistinen, Ina and Brauner, Annelie and Altman, Daniel and Broliden, Kristina and Bohm-Starke, Nina},
title = {Vaginal chlorhexidine gluconate versus fluconazole for recurrent vulvovaginal candidiasis: A randomized noninferiority trial},
journal = {PLOS One},
year = {2026},
doi = {10.1371/journal.pone.0340862}
}
EUVIMED